酶诱导作用会增强丙吡胺的代谢并降低其疗效吗？
Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
作者信息
Aitio M L, Vuorenmaa T
出版信息
Br J Clin Pharmacol. 1980 Feb;9(2):149-52. doi: 10.1111/j.1365-2125.1980.tb05825.x.
Abstract
1 Monitoring plasma levels of mono-N-dealkyldisopyramide (MND), the most important metabolite of disopyramide, has been considered unnecessary. 2 We measured plasma levels of both disopyramide and MND in 64 consecutive patients receiving long term oral therapy with disopyramide. 3 Six patients were found with high plasma levels of MND, and simultaneously low levels of disopyramide. 4 Three of these patients were taking simultaneously phenytoin. The other three had a relatively high dose of disopyramide with regard to their renal function. One patient had terminal uremia, three had less severe renal dysfunction. 5 The underlying mechanism and clinical significance of the findings are discussed.
摘要
- 监测双异丙吡胺最重要的代谢产物单-N-去烷基双异丙吡胺（MND）的血浆水平被认为没有必要。2. 我们对64例连续接受双异丙吡胺长期口服治疗的患者测定了双异丙吡胺和MND的血浆水平。3. 发现6例患者MND血浆水平高，同时双异丙吡胺水平低。4. 其中3例患者同时服用苯妥英。另外3例患者相对于其肾功能而言双异丙吡胺剂量较高。1例患者有终末期尿毒症，3例有不太严重的肾功能不全。5. 讨论了这些发现的潜在机制和临床意义。
相似文献
1
Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction?
Br J Clin Pharmacol. 1980 Feb;9(2):149-52. doi: 10.1111/j.1365-2125.1980.tb05825.x.
2
The effect of enzyme induction on the metabolism of disopyramide in man.
Br J Clin Pharmacol. 1981 Mar;11(3):279-85. doi: 10.1111/j.1365-2125.1981.tb00535.x.
3
Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
Br J Clin Pharmacol. 1981 Apr;11(4):369-75. doi: 10.1111/j.1365-2125.1981.tb01134.x.
4
Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Br J Clin Pharmacol. 1982 Nov;14(5):673-6. doi: 10.1111/j.1365-2125.1982.tb04955.x.
5
6
Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
Biopharm Drug Dispos. 1983 Apr-Jun;4(2):103-12. doi: 10.1002/bdd.2510040202.
7
The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Int J Clin Pharmacol Ther Toxicol. 1982 May;20(5):219-26.
8
[Accumulation of a disopyramide metabolite in renal failure].
Nihon Jinzo Gakkai Shi. 1993 Sep;35(9):1065-71.
9
Interactions with the cardiac cholinergic system: effects of disopyramide and its mono-N-dealkylated metabolite.
Life Sci. 1992;50(20):PL161-6. doi: 10.1016/0024-3205(92)90148-i.
10
Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Br J Clin Pharmacol. 1984 Nov;18(5):779-84. doi: 10.1111/j.1365-2125.1984.tb02542.x.
引用本文的文献
1
Machine Learning in Drug Metabolism Study.
Curr Drug Metab. 2022;23(13):1012-1026. doi: 10.2174/1389200224666221227094144.
2
Therapeutic drug monitoring of antiarrhythmic drugs.
Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004.
3
Antiarrhythmic agents: drug interactions of clinical significance.
Drug Saf. 2000 Dec;23(6):509-32. doi: 10.2165/00002018-200023060-00003.
4
Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
Br J Clin Pharmacol. 1981 Apr;11(4):369-75. doi: 10.1111/j.1365-2125.1981.tb01134.x.
5
The effect of enzyme induction on the metabolism of disopyramide in man.
Br J Clin Pharmacol. 1981 Mar;11(3):279-85. doi: 10.1111/j.1365-2125.1981.tb00535.x.
6
Enhanced drug metabolism and renal dysfunction.
Br J Clin Pharmacol. 1981 Jan;11(1):92-3. doi: 10.1111/j.1365-2125.1981.tb01109.x.
7
Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Br J Clin Pharmacol. 1982 Nov;14(5):673-6. doi: 10.1111/j.1365-2125.1982.tb04955.x.
8
Pharmacokinetic interactions with antiepileptic drugs.
Clin Pharmacokinet. 1982 Jan-Feb;7(1):57-84. doi: 10.2165/00003088-198207010-00004.
9
Therapeutic drug monitoring of antiarrhythmic agents.
Clin Pharmacokinet. 1982 Mar-Apr;7(2):125-48. doi: 10.2165/00003088-198207020-00003.
10
Drug interactions with phenytoin.
Drugs. 1981 Feb;21(2):120-37. doi: 10.2165/00003495-198121020-00003.
本文引用的文献
1
Diphenylhydantoin metabolism in uremia.
N Engl J Med. 1971 Sep 16;285(12):648-52. doi: 10.1056/NEJM197109162851202.
2
Determination of disopyramide and its mono-N-dealkylated metabolite in blood serum and urine.
J Chromatogr. 1975 Mar 19;106(1):151-8. doi: 10.1016/s0021-9673(01)81057-8.
3
The pharmacokinetics of Norpace.
Angiology. 1975 Jan;26(1 Pt 2):85-98.
4
The excretion of D-glucaric acid in the urine of human volunteers following the administration of disopyramide.
J Int Med Res. 1976;4(1 Suppl):59-60.
5
Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.
J Pharmacokinet Biopharm. 1976 Jun;4(3):199-230. doi: 10.1007/BF01063614.
6
Responses of the D-glucuronic acid pathway in rat tissues to treatment with tetrachlorodibenzodioxin.
Xenobiotica. 1978 Jul;8(7):397-402. doi: 10.3109/00498257809070023.
7
Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle.
Eur J Pharmacol. 1978 Jun 15;49(4):389-94. doi: 10.1016/0014-2999(78)90313-8.
8
Induction of disopyramide N-dealkylation by phenobarbital and disopyramide in rat liver.
Arch Int Pharmacodyn Ther. 1979 May;239(1):16-23.
9
Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
Drugs. 1978 May;15(5):331-68.
10
Some pharmacological effects of disopyramide and a metabolite.
J Int Med Res. 1976;4(1 Suppl):5-7.
Zotero 插件